NTR-101

AXP000237.1 · Phage therapy

Platform
phage preparation
Originator
Nterica Bio
Sponsor
Nterica Bio

Names

NameTypeSource
NTR-101preferred name, codecurator, ctgov

Virus

Role
Phage
Family
Caudoviricetes
Virus
bacteriophage preparation against cytolysin-positive Enterococcus faecalis
Replication
replicating
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06750588Safety and Tolerability of NTR-101 in Patients With Acute Alcohol-Associated HepatitisNot yet recruitingPhase 12025-11-052026-0412Alcohol-Associated Hepatitis

Recent changes

No changes recorded in its trials yet.

Notes

Phage preparation in a phase 1 trial in acute alcohol-associated hepatitis (NCT06750588), where the target is a cytolysin-producing gut bacterium rather than a wound or lung pathogen. The registration names the target as cytolysin-positive Enterococcus faecalis and screens patients both for E. faecalis and for susceptibility to NTR-101; the cytolysin link to alcohol-associated hepatitis is Duan 2019, Nature 575:505-511.

How to cite

NTR-101 (AXP000237.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000237.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.